Prescription opioid abuse: Problems and responses

Preventive Medicine

Volumn 80, Issue , 2015, Pages 5-9

  Compton, Wilson M ^a   Boyle, Maureen ^a   Wargo, Eric ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Overdose; Prescription opioid abuse

Indexed keywords

NARCOTIC ANALGESIC AGENT;

CLINICAL DECISION MAKING; CRIMINAL JUSTICE; DRUG ABUSE; DRUG MONITORING; HEALTH PROGRAM; HUMAN; LAW ENFORCEMENT; MEDICAL EDUCATION; NOTE; PRACTICE GUIDELINE; PRESCRIPTION OPIOID ABUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; CHRONIC PAIN; DRUG OVERDOSE; EVIDENCE BASED PRACTICE; INAPPROPRIATE PRESCRIBING; MORTALITY; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; PUBLIC HEALTH; UNITED STATES;

CHRONIC PAIN; DRUG OVERDOSE; EVIDENCE-BASED PRACTICE; HUMANS; INAPPROPRIATE PRESCRIBING; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; PRIMARY PREVENTION; PUBLIC HEALTH; UNITED STATES;

EID: 84943662053     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2015.04.003     Document Type: Note

References (62)

1. American Society of Addiction Medicine (ASAM) The ASAM Standards of Care for the Addiction Specialist Physician (Accessed March 10, 2015). http://www.asam.org/docs/default-source/practice-support/quality-improvement/asam-standards-of-care.pdf?sfvrsn=10.
2. Anon National Institutes of Health Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain, September 29-30, 2014. Executive Summary 2014, (https://prevention.nih.gov/docs/programs/p2p/ODPPainPanelStatementFinal_10-02-14.pdf).
3. Anon NIH Pain Consortium Centers of Excellence in Pain Education (CoEPEs) (Accessed December 24, 2014). http://painconsortium.nih.gov/coepes.html.
4. Banta-Green C.J., Beletsky L., Schoeppe J.A., Coffin P.O., Kuszler P.C. Police officers' and paramedics' experiences with overdose and their knowledge and opinions of Washington State's drug overdose-naloxone-Good Samaritan law. J. Urban Health 2013, 90(6):1102-1111. 10.1007/s11524-013-9814-y.
5. Bohnert A.B., Valenstein M., Bair M.J., et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011, 305(13):1315-1321. 10.1001/jama.2011.370.
6. Brush D.E. Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia. J. Med. Toxicol. 2012, 8(4):387-392. 10.1007/s13181-012-0260-0.
7. CDC Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR 2011, 60(43):1487-1492. (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm. Accessed December 19, 2014).
8. CDC Decline in drug overdose deaths After State Policy Changes-Florida, 2010-2012. MMWR 2014, 63(26):569-574. (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6326a3.htm. Accessed December 19, 2014).
9. Centers for Disease Control and Prevention (CDC) Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb. Mortal. Wkly Rep. 2012, 61(6):101-105.
10. Centers for Disease Control, National Center for Health Statistics Multiple cause-of-death data, 1999-2013. CDC WONDER 2014, (http://wonder.cdc.gov/mcd.html. Accessed February 26, 2015).
11. Centers for Disease Control and Prevention (CDC) Common Elements in Guidelines for Prescribing Opioids for Chronic Pain (Accessed March 10, 2015). http://ttp://www.cdc.gov/HomeandRecreationalSafety/overdose/guidelines.html.
12. Chandler R.K., Fletcher B.W., Volkow N.D. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009, 301(2):183-190. 10.1001/jama.2008.976.
13. Chou R., Deyo R., Devine B., et al. The effectiveness and risks of long-term opioid treatment of chronic pain 2014, Agency for Healthcare Research and Quality, Rockville, MD, (http://www.ncbi.nlm.nih.gov/books/NBK258809/pdf/TOC.pdf. Published September 2014. Accessed December 19, 2014).
14. Cicero T.J., Ellis M.S. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry 2015, (Published, online March 11, 2015). 10.1001/jamapsychiatry.2014.3043.
15. Cicero T.J., Ellis M.S., Surratt H.L., Kurtz S.P. The changing face of heroin use in the United States: a retrospective analysis of the past 50years. JAMA Psychiatry 2014, 71(7):821-826. 10.1001/jamapsychiatry.2014.366.
16. Clark A.K., Wilder C.M., Winstanley E.L. A systematic review of community opioid overdose prevention and naloxone distribution programs. J. Addict. Med. 2014, 8(3):153-163. 10.1097/ADM.0000000000000034.
17. Coffin P.O., Sullivan S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann. Intern. Med. 2013, 158(1):1-9. 10.7326/0003-4819-158-1-201301010-00003.
18. Crozier M.K., Mcmillan S., Hudson S., Jones S. The eastern North Carolina opioid prescribers project: a model continuing medical education workshop. J. Opioid Manag. 2010, 6(5):359-364.
19. Davis C.S., Ruiz S., Glynn P., Picariello G., Walley A.Y. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am. J. Public Health 2014, 104(8):e7-e9. 10.2105/AJPH.2014.302062.
20. Dhalla I.A., Mamdani M.M., Gomes T., et al. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Can. Fam. Physician 2011, 57(3):e92-e96. (Mar).
21. Dunn K.M., Saunders K.W., Rutter C.M., et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann. Int. Med. 2010, 152(2):85-92. 10.7326/0003-4819-152-2-201001190-00006.
22. Fang L., Schinke S.P. Two-year outcomes of a randomized, family-based substance use prevention trial for Asian American adolescent girls. J. Soc. Psychol. Addict. Behav. 2013, 27(3):788-798. 10.1037/a0030925.
23. Franklin G.G., Sabel J., Jones C.M., et al. A comprehensive approach to address the prescription opioid epidemic in Washington State: milestones and lessons learned. Am. J. Public Health 2015, 105(3):463-469. 10.2105/AJPH.2014.302367.
24. Gifford E.J., Eldred L.M., McCutchan S.A., et al. The effects of participation level on recidivism: a study of drug treatment courts using propensity score matching. Subst. Abuse Treat. Prev. Policy 2014, 9:40. 10.1186/1747-597X-9-40.
25. Gordon M.S., Kinlock T.W., Schwartz R.P., et al. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014, 142:33-40. 10.1016/j.drugalcdep.2014.05.011.
26. Haegerich T.M., Paulozzi L.J., Manns B.J., Jones C.M. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014, 145:34-47. 10.1016/j.drugalcdep.2014.10.001.
27. Højsted J., Nielsen P.R., Guldstrand S.K., et al. Classification and identification of opioid addiction in chronic pain patients. Eur. J. Pain 2010, 14(10):1014-1020. 10.1016/j.ejpain.2010.04.006.
28. IMS Health Vector One®: national, years 1991-2011. Data Extracted 2012.
29. International Narcotics Control Board Report of the International Narcotics Control Board for 2008 2009, 20. United Nations Publications, New York, NY.
30. Johnson E.M., Porucznik C.A., Anderson J.W., Rolfs R.T. State-level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program. Pain Med. 2011, 12(Suppl. 2):S66-S72. 10.1111/j.1526-4637.2011.01126.x.
31. Jones C.M., Paulozzi L.J., Mack K.A. Research Letter: Sources of prescription opioid pain relievers by frequency of past-year nonmedical use United States, 2008-2011. JAMA Int. Med. 2014, 174(5):802-803. 10.1001/jamainternmed.2013.12809.
32. Juurlink D.N., Dhalla I.A. Dependence and addiction during chronic opioid therapy. J. Med. Toxicol. 2012, 8(4):393-399. 10.1007/s13181-012-0269-4.
33. Kahan M., Gomes T., Juurlink D.N., et al. Effect of a course-based intervention and effect of medical regulation on physicians' opioid prescribing. Can. Fam. Physician 2013, 59(5):e231-e239.
34. Knudsen H.K., Abraham A.J., Roman P.M. Adoption and implementation of medications in addiction treatment programs. J. Addict. Med. 2011, 5(1):21-27. 10.1097/ADM.0b013e3181d41ddb.
35. LawAtlas: The Policy Surveillance Portal Good Samaritan Overdose Prevention Laws (Accessed March 10, 2015). http://lawatlas.org/files/upload/2012.12.22_Good%20Sam_EssentialInformation.pdf.
36. Lee M., Silverman S.M., Hansen H., et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011, 14(2):145-161.
37. Lofwall M.R., Martin J., Tierney M., et al. Buprenorphine diversion and misuse in outpatient practice. J. Addict. Med. 2014, 8(5):327-332. 10.1097/ADM.0000000000000029.
38. Martin B.C., Fan M.-Y., Edlund M.J., et al. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J. Gen. Intern. Med. 2011, 26(12):1450-1457. 10.1007/s11606-011-1771-0.
39. McDonald D.C., Carlson K.E. Estimating the prevalence of opioid diversion by "doctor shoppers" in the United States. PLoS One 2013, 8(7):e69241. 10.1371/journal.pone.0069241.
40. Minozzi S., Amato L., Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction 2013, 108(4):688-698. 10.1111/j.1360-0443.2012.04005.x.
41. Mitchell O., Wilson D.B., Eggers A., et al. Assessing the effectiveness of drug courts on recidivism: a meta-analytic review of traditional and non-traditional drug courts. J. Crim. Just. 2012, 40(1):60-71. 10.1016/j.jcrimjus.2011.11.009.
42. Modarai F., Mack K., Hicks P., et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013, 132(1-2):81-86. 10.1016/j.drugalcdep.2013.01.006.
43. Muhuri P.K., Gfroerer J.C., Davies M.C. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ [Center for Behavioral Health Statistics and Quality] Data Review 2013, (August, http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.htm. Accessed March 16, 2015).
44. NIDAMED Opioid and Pain Management CMEs/CEs (Accessed December 24, 2014). http://www.drugabuse.gov/opioid-pain-management-cmesces.
45. Paulozzi L.J., Budnitz D.S., Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol. Drug Saf. 2006, 15(9):618-627. 10.1002/pds.1276.
46. Ray B., O'Donnell D., Kahre K. Police officer attitudes towards intranasal naloxone training. Drug Alcohol Depend. 2015, 146:107-110. 10.1016/j.drugalcdep.2014.10.026.
47. Reifler L.M., Droz D., Bailey J.E., et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse?. Pain Med. 2012, 13(3):434-442. 10.1111/j.1526-4637.2012.01327.x.
48. Santos A. Combating pharmaceutical diversion: targeting 'rogue pain clinics' and 'pill mills' (Presented May 2013. Accessed March 10, 2015). http://www.deadiversion.usdoj.gov/mtgs/pharm_awareness/conf_2013/may_2013/santosII.pdf.
49. Schinke S.P., Fang L., Cole K.C. Computer-delivered, parent-involvement intervention to prevent substance use among adolescent girls. Prev. Med. 2009, 49(5):429-435. 10.1016/j.ypmed.2009.08.001.
50. Schwartz R.P., Gryczynski J., O'Grady K.E., et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am. J. Public Health 2013, 103(5):917-922. 10.2105/AJPH.2012.301049.
51. Spoth R., Trudeau L., Shin C., et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three RCTs with late adolescents and young adults. Am. J. Public Health 2013, 103(4):665-672. 10.2105/AJPH.2012.301209.
52. Substance Abuse and Mental Health Services Administration Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 14-4863 2014, Substance Abuse and Mental Health Services Administration, Rockville, MD, (http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. Accessed December 19, 2014).
53. Substance Abuse and Mental Health Services Administration (SAMHSA) Opioid Overdose Toolkit (Accessed March 10, 2015). http://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit-Updated-2014/SMA14-4742.
54. Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment (Accessed March 10, 2015). http://www.samhsa.gov/medication-assisted-treatment.
55. Substance Abuse and Mental Health Services Administration (SAMHSA) Buprenorphine Physician and Treatment Program Locator (Accessed March 10, 2015). http://buprenorphine.samhsa.gov/bwns_locator/index.html.
56. Swedlow A., Ireland J., Johnson G. Prescribing patterns of schedule II opioids in California Workers' Compensation 2011, California Workers' Compensation Institute, Oakland, CA, (http://www.cwci.org/document.php?file=1438.pdf. Accessed December 22, 2014).
57. The Office of the National Coordinator for Health Information Technology PDMPConnect: Making Connections with PDMPs (Accessed December 19, 2014). http://www.healthit.gov/pdmp/PDMPConnect.
58. Trust for America's Health Prescription Drug Abuse: Strategies to Stop the Epidemic 2013 (Accessed March 10, 2015). http://healthyamericans.org/reports/drugabuse2013/TFAH2013RxDrugAbuseRpt12_no_embargo.pdf.
59. Unick G.J., Rosenblum D., Mars S., Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One 2013, 8. (e54496-e54496). 10.1371/journal.pone.0054496.
60. Volkow N.D., Frieden T.R., Hyde P.S., et al. Medication-assisted therapies-tackling the opioid-overdose epidemic. N. Engl. J. Med. 2014, 370(22):2063-2066. 10.1056/NEJMp1402780.
61. Walley A.Y., Xuan Z., Hackman H.H., et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013, 346:f174. 10.1136/bmj.f174.
62. Wermeling D.P. A response to the opioid overdose epidemic: naloxone nasal spray. Drug Deliv. Transl. Res. 2013, 3(1):63-74. 10.1007/s13346-012-0092-0.